Study examines thinning of heart muscle wall among patients with coronary artery disease
Among patients with coronary artery disease referred for cardiovascular magnetic resonance and found to have regional myocardial wall thinning (of the heart muscle), limited scar burden was associated with improved contraction of the heart and reversal of wall thinning after revascularization, suggesting that myocardial thinning is potentially reversible, according to a study appearing in the March 6 issue of JAMA.
Regional myocardial wall thinning is thought to represent chronic myocardial infarction. "However, recent case reports incorporating the use of delayed-enhancement cardiovascular magnetic resonance (CMR) imaging raise the possibility that this viewpoint is incorrect. These single-patient reports indicate that myocardial regions with severe wall thinning do not necessarily consist entirely of scar tissue but instead may have minimal or no scarring. Thus, some areas of myocardial thinning may represent viable myocardium and have the potential for recovery of function," according to background information in the article.
Dipan J. Shah, M.D., of Duke University Medical Center, Durham, N.C., and colleagues conducted a study to evaluate patients with regional myocardial wall thinning and to determine scar burden and potential for functional improvement. The study, conducted from August 2000 through January 2008, included 1,055 patients with known coronary artery disease (CAD) who underwent CMR imaging.
"Of 201 patients [19 percent] identified by CMR as having wall thinning, most had significant left ventricular dysfunction, multivessel CAD, and thinning of a substantial portion of the left ventricle. Among this cohort, 18 percent of thinned regions had limited or no scarring observed using delayed-enhancement CMR. Because the lack of scarring was associated with significant contractile improvement and reverse remodeling with resolution of wall thinning following revascularization, we believe the data indicate that myocardial thinning is potentially reversible and therefore should not be considered a permanent state," the authors write.
"… we believe our study provides new insights into the pathophysiology of thinned myocardium and more broadly the process of reversible ischemic injury. The data show that thinned myocardium may consist of limited scar tissue and can recover function— concepts that are both inconsistent with current views.
"The findings provide rationale for future experimental studies on reversible ischemic injury as well as for clinical studies prospectively testing whether CMR guidance for coronary revascularization decisions can improve patient outcome," the researchers conclude.
In an accompanying editorial, Deepak K. Gupta, M.D., of Brigham and Women's Hospital, Boston, and colleagues write that the two cardiovascular imaging studies in this issue of JAMA "address the important issue of how supplemental noninvasive imaging studies can assist the cardiovascular specialist."
"Together these reports provide a consistent message that detailed assessments of tissue composition, in particular fibrosis by late gadolinium enhancement (LGE), may provide superior information than morphologic parameters, in both ischemic and nonischemic cardiomyopathies. Collectively, these and other studies demonstrate that CMR with LGE imaging adds to the practitioner's armamentarium for assessment of cardiac structure and function and augments diagnostic and prognostic capabilities."
"However, the clinical challenge remains in deciding which patients to evaluate with CMR and LGE and what to do with the findings. Nevertheless, whether CMR with LGE imaging would provide better assessment for nonischemic or ischemic heart disease for guiding decisions regarding revascularization or implantable cardioverter defibrillator placement and the subsequent influence on prognosis remain intriguing and warrant further study. At this point, for the practicing physician, the incremental information gained from CMR with LGE imaging from these 2 studies, albeit novel and supportive, is not yet sufficient to alter clinical practice guidelines."
More information: JAMA. 2013;309(9):909-918
JAMA. 2013;309(9):929-930
Journal reference:
Journal of the American Medical Association
Provided by
JAMA and Archives Journals
-
Cardiac study evaluates prevalence of unrecognized heart attacks among older adults
Sep 04, 2012 |
not rated yet |
0
-
Cardiac disorder may affect broader range of patients than previously reported
Jul 19, 2011 |
not rated yet |
0
-
New hidden heart attack culprit identified in women
Sep 26, 2011 |
not rated yet |
0
-
Study examines outcomes of erythropoietin use for heart attack patients undergoing PCI
May 10, 2011 |
not rated yet |
0
-
New imaging technology reveals prevalence of 'silent' heart attacks
Apr 21, 2009 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
The Durability of Bone: Long Falls
5 hours ago
-
Is energy convertible to matter?
6 hours ago
-
Rotating electron as a dipole is this right?
9 hours ago
-
Dipole term in multipole expansion
13 hours ago
-
Bubbles in a Pre-Boiling/Boiling pot of water
14 hours ago
-
Assumptions of Griffith's fracture theory
May 21, 2013
- More from Physics Forums - Classical Physics
More news stories
Biodegradable stent proves non-inferior to drug-eluting stent
The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent ...
Cardiology
9 hours ago |
5 / 5 (1) |
0
Post-approval TAVI registry shows high rates of device success at one year
One-year results from SOURCE XT – one of the largest, post-approval transcatheter aortic valve implantation (TAVI) registries to-date – reported today at EuroPCR 2013 show good clinical outcomes in routine clinical practice, ...
Cardiology
9 hours ago |
not rated yet |
0
Antidepressant reduces stress-induced heart condition
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
Cardiology
10 hours ago |
5 / 5 (1) |
0
|
Study identifies superior hypertension treatment, efficacy between sexes
(Medical Xpress)—In a recent subgroup analysis of the largest blood pressure treatment trial in history, University of Alabama at Birmingham (UAB) researchers found that women and men react the same to ...
Cardiology
18 hours ago |
5 / 5 (1) |
0
Evaluating a new way to open clogged arteries
Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents. While generally effective, each of these treatments ...
Cardiology
19 hours ago |
4.6 / 5 (5) |
0
|
If you can remember it, you can remember it wrong
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
B vitamins could delay dementia
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
Insight into the dazzling impact of insulin in cells
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
New sleeping pill poised to hit US markets
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
Reducing caloric intake delays nerve cell loss
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
Drugs found to both prevent and treat Alzheimer's disease in mice
Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.